Cultural acknowledgement

The Department of Health acknowledges the Traditional Custodians of the lands, waters and seas across the State of Queensland on which we work and live. We also acknowledge First Nations peoples in Queensland are both Aboriginal Peoples and Torres Strait Islander Peoples and pay respect to the Aboriginal and Torres Strait Islander Elders past, present and emerging.

Table of Contents
1 Introduction ......................................................................................................................... 3
  1.1 Funding .......................................................................................................................... 3
  1.2 Conflict of interest ......................................................................................................... 3
  1.3 Development process ...................................................................................................... 3
  1.4 Summary of changes ........................................................................................................ 3
2 Methodology ....................................................................................................................... 4
  2.1 Topic identification ......................................................................................................... 4
  2.2 Scope ................................................................................................................................ 4
  2.3 Clinical questions .......................................................................................................... 4
  2.4 Search strategy .............................................................................................................. 5
    2.4.1 Keywords .................................................................................................................. 5
  2.5 Consultation .................................................................................................................... 6
  2.6 Endorsement ................................................................................................................... 6
  2.7 Citation ............................................................................................................................. 6
3 Levels of evidence ................................................................................................................ 7
  3.1 Summary recommendations .......................................................................................... 7
4 Implementation .................................................................................................................... 8
  4.1 Guideline resources ......................................................................................................... 8
  4.2 Suggested resources ........................................................................................................ 8
  4.3 Implementation measures ............................................................................................... 8
    4.3.1 QCG measures .......................................................................................................... 8
    4.3.2 Hospital and Health Service measures ..................................................................... 8
    4.3.3 Implications for implementation ............................................................................. 8
  4.4 Quality measures ............................................................................................................ 9
  4.5 Areas for future research ............................................................................................... 9
  4.6 Safety and quality .......................................................................................................... 9
References ................................................................................................................................ 18
Acknowledgements ............................................................................................................... 18

List of Tables
Table 1. Summary of change .................................................................................................. 3
Table 2. Scope framework ....................................................................................................... 4
Table 3. Basic search strategy ................................................................................................. 5
Table 4. Major guideline development processes .................................................................. 5
Table 5. Summary recommendations ...................................................................................... 6
Table 6. NSQHS Standard 1 .................................................................................................. 7
Table 7. Clinical quality measures .......................................................................................... 9
Table 8. NSQHS ...................................................................................................................... 10

© State of Queensland (Queensland Health) 2023

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For further information contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au. For permissions beyond the scope of this licence contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au

Refer to online version, destroy printed copies after use
1 Introduction
This document is a supplement to the Queensland Clinical Guideline (QCG) Fetal movements. It provides supplementary information regarding guideline development, makes summary recommendations, suggests measures to assist implementation and quality activities and summarises changes (if any) to the guideline since original publication. Refer to the guideline for abbreviations, acronyms, flow charts and acknowledgements.

1.1 Funding
The development of this guideline was funded by Healthcare Improvement Unit, Queensland Health. Consumer representatives were paid a standard fee. Other working party members participated on a voluntary basis.

1.2 Conflict of interest
Declarations of conflict of interest were sought from working party members as per the Queensland Clinical Guidelines Conflict of Interest statement.

1.3 Development process
This version of the guideline followed the QCG [Peer review] process

1.4 Summary of changes
Queensland clinical guidelines are reviewed every 5 years or earlier if significant new evidence emerges. Table 1 provides a summary of changes made to the guidelines since original publication.

<table>
<thead>
<tr>
<th>Publication date</th>
<th>Identifier</th>
<th>Summary of major change</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2018</td>
<td>MN18.46-V1-R23</td>
<td>First publication</td>
</tr>
<tr>
<td>QCG Steering Committee Statewide Maternity and Neonatal Clinical Network (QLD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>September 2020</td>
<td>MN18.46-V2-R23</td>
<td>Tables: Fetal maternal transfusion and Ongoing management</td>
</tr>
<tr>
<td>QCG Steering Committee</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flowchart: Altered fetal movements</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flow cytometry or Kleihauer-Betke</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Added: Consult with haematology service at testing pathology laboratory for preferred test</td>
</tr>
<tr>
<td>July 2023</td>
<td>MN23.46-V3-R28</td>
<td>Peer Review:</td>
</tr>
<tr>
<td>Queensland Maternity and Neonatal Clinical Network</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Formatting updated</td>
</tr>
<tr>
<td></td>
<td></td>
<td>References updated</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flow amended</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flowcharts aligned with text</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elements of Queensland Clinical Guidelines Standard care removed</td>
</tr>
</tbody>
</table>
2 Methodology
Queensland Clinical Guidelines (QCG) follows a rigorous process of guideline development. This process was endorsed by the Queensland Health Patient Safety and Quality Executive Committee in December 2009. The guidelines are best described as ‘evidence informed consensus guidelines’ and draw from the literature, the evidence base of existing national and international guidelines and the expert opinion of the working party.

2.1 Topic identification
The topic was identified as a priority by the Stillbirth guideline review working party in 2017 and endorsed for development by the QCG steering committee in February 2018.

2.2 Scope
The scope of the guideline was determined using the following framework.

Table 2. Scope framework

<table>
<thead>
<tr>
<th>Scope framework</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Pregnant women during the antenatal period</td>
</tr>
<tr>
<td>Purpose</td>
<td>Identify relevant evidence related to:</td>
</tr>
<tr>
<td></td>
<td>• Normal fetal movements</td>
</tr>
<tr>
<td></td>
<td>• Diagnosis, assessment, and management of changed or decreased fetal movements</td>
</tr>
<tr>
<td>Outcome</td>
<td>Support:</td>
</tr>
<tr>
<td></td>
<td>• Woman’s understanding of normal fetal movements and when to seek advice</td>
</tr>
<tr>
<td></td>
<td>• Accurate assessment of changed or decreased fetal movements</td>
</tr>
<tr>
<td></td>
<td>• Best practice/investigations management during pregnancy</td>
</tr>
<tr>
<td>Exclusions</td>
<td>• Routine antenatal, intrapartum and postpartum care</td>
</tr>
<tr>
<td></td>
<td>• Ongoing management of woman following abnormal assessment requiring further investigations</td>
</tr>
<tr>
<td></td>
<td>• CTG monitoring/interpretation</td>
</tr>
<tr>
<td></td>
<td>• Elements of care specific to Queensland Clinical Guideline Standard care</td>
</tr>
</tbody>
</table>

2.3 Clinical questions
The following clinical questions were generated to inform the guideline scope and purpose:

- How are fetal movements described?
- What are the normal patterns of fetal movements?
- What factors affect fetal movements?
- How are fetal movements assessed?
- What is the management of changed or decreased fetal movements?
2.4 Search strategy

A search of the literature was conducted during December 2022–March 2023. A further search was conducted in April 2023. The QCG search strategy is an iterative process that is repeated and amended as guideline development occurs (e.g. if additional areas of interest emerge, areas of contention requiring more extensive review are identified or new evidence is identified). All guidelines are developed using a basic search strategy. This involves both a formal and informal approach.

Table 3. Basic search strategy

<table>
<thead>
<tr>
<th>Step</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| 1.   | Review clinical guidelines developed by other reputable groups relevant to the clinical speciality  
• This may include national and/or international guideline writers, professional organisations, government organisations, state based groups.  
• This assists the guideline writer to identify:  
  o The scope and breadth of what others have found useful for clinicians and informs the scope and clinical question development  
  o Identify resources commonly found in guidelines such as flowcharts, audit criteria and levels of evidence  
  o Identify common search and key terms  
  o Identify common and key references |
| 2.   | Undertake a foundation search using key search terms  
• Construct a search using common search and key terms identified during Step 1 above  
• Search the following databases  
  o PubMed  
  o CINAHL  
  o Medline  
  o Cochrane Central Register of Controlled Trials  
  o EBSCO  
  o Embase  
• Studies published in English less than or equal to 5 years previous are reviewed in the first instance. Other years may be searched as are relevant to the topic  
• Save and document the search  
• Add other databases as relevant to the clinical area |
| 3.   | Develop search word list for each clinical question  
• This may require the development of clinical sub-questions beyond those identified in the initial scope.  
• Using the foundation search performed at Step 2 as the baseline search framework, refine the search using the specific terms developed for the clinical question  
• Save and document the search strategy undertaken for each clinical question |
| 4.   | Other search strategies  
• Search the reference lists of reports and articles for additional studies  
• Access other sources for relevant literature  
  o Known resource sites  
  o Internet search engines  
  o Relevant textbooks |

2.4.1 Keywords

The following keywords were used in the basic search strategy: fetal movements, decreased fetal movements, fetal activity, feto-maternal haemorrhage, fetal growth restriction, fetal compromise, placental insufficiency, fetal monitoring, stillbirth.

Other keywords may have been used for specific aspects of the guideline.
2.5 Consultation
Major consultative and development processes occurred between March 2023 and April 2023.

Table 4. Major guideline development processes

<table>
<thead>
<tr>
<th>Process</th>
<th>Activity</th>
</tr>
</thead>
</table>
| Original development           | • Original consultative and development processes occurred between March 2023 and April 2023  
                                  • This included formation of a working party and statewide consultation as per usual QCG process  
                                  • A survey of clinician opinion was also conducted |
| Decision for peer review       | • A review of the guideline scope, clinical questions and current literature was undertaken in February 2023  
                                  • Areas of clinical practice change were identified  
                                  • Clinical leads  
                                      o Reviewed the previous scope and version of the guideline  
                                      o Reviewed identified areas of clinical practice change  
                                      o Confirmed aspects of the guideline for update and new inclusions  
                                      o Reached consensus agreement that a peer review process was appropriate |
| Consultation                   | • Expert clinicians and a consumer representative were identified by the clinical leads and invited to peer review the updated guideline in April 2023  
                                  • All invited members accepted |

2.6 Endorsement
The guideline was endorsed by the:
• Queensland Clinical Guidelines Steering Committee in July 2023
• Queensland Maternity and Neonatal Clinical Network in July 2023

2.7 Citation
The recommended citation of Queensland Clinical Guidelines is in the following format:


EXAMPLE:
3 Levels of evidence

Summary recommendations were informed by:

- Review of literature
- Expertise and experience of clinical leads and working party
- Statewide consultation
- Established Queensland Clinical Guidelines development process

3.1 Summary recommendations

Summary recommendations and levels of evidence are outlined in Table 5. Summary recommendations.

Table 5. Summary recommendations

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Advise woman to contact healthcare provider at any time if concerned about</td>
<td>Consensus</td>
</tr>
<tr>
<td>fetal movements</td>
<td></td>
</tr>
<tr>
<td>2. Advise all women about normal fetal movements early in pregnancy</td>
<td>Consensus</td>
</tr>
<tr>
<td>3. Advise women against the use of ‘kick charts’</td>
<td>Consensus</td>
</tr>
<tr>
<td>4. Recommend clinical assessment of woman and fetus within two hours of</td>
<td>Consensus</td>
</tr>
<tr>
<td>presentation with decreased fetal movements</td>
<td></td>
</tr>
<tr>
<td>5. Consider testing for feto-maternal transfusion by Kleihauer-Betke or flow</td>
<td>Consensus</td>
</tr>
<tr>
<td>cytometry if concerns with fetal movements</td>
<td></td>
</tr>
<tr>
<td>6. Perform obstetric USS if concerns with fetal movements—timing based on</td>
<td>Consensus</td>
</tr>
<tr>
<td>clinical assessment, CTG, gestational age and recent USS findings</td>
<td></td>
</tr>
</tbody>
</table>
4 Implementation

This guideline is applicable to all Queensland public and private maternity facilities. It can be downloaded in Portable Document Format (PDF) from www.health.qld.gov.au/qcg

4.1 Guideline resources

The following guideline components are provided on the website as separate resources:

- Flowchart: Altered fetal movements

The following guideline components are provided on the QCG website as links to external resources:

- Education resource: Stillbirth CRE Safer Baby Bundle e-learning modules
- Parent information: Stillbirth CRE Safer Baby brochure

4.2 Suggested resources

During the development process stakeholders identified additional resources with potential to complement and enhance guideline implementation and application. The following resources have not been sourced or developed by QCG but are suggested as complimentary to the guideline:

- Local protocols regarding transfer for obstetric ultrasound, when required

4.3 Implementation measures

Suggested activities to assist implementation of the guideline are outlined below.

4.3.1 QCG measures

- Notify Chief Executive Officer and relevant stakeholders
- Monitor emerging new evidence to ensure guideline reflects contemporaneous practice
- Capture user feedback
- Record and manage change requests

4.3.2 Hospital and Health Service measures

Initiate, promote and support local systems and processes to integrate the guideline into clinical practice, including:

- Hospital and Health Service (HHS) Executive endorse the guidelines and their use in the HHS and communicate this to staff
- Promote the introduction of the guideline to relevant health care professionals
- Support education and training opportunities relevant to the guideline and service capabilities
- Align clinical care with guideline recommendations
- Undertake relevant implementation activities as outlined in the Guideline implementation checklist available at www.health.qld.gov.au/qcg

4.3.3 Implications for implementation

The following areas may have implications for local implementation of the guideline recommendations. It is suggested they be considered for successful guideline implementation.

- Economic considerations including opportunity costs
- Human resource requirements including clinician skill mix and scope of practice
- Clinician education and training
- Equipment and consumables purchase and maintenance
- Consumer acceptance
- Model of care and service delivery
4.4 Quality measures
Auditing of guideline recommendations and content assists with identifying quality of care issues and provides evidence of compliance with the National Safety and Quality Health Service (NSQHS) Standards [Refer to Table 6. NSQHS Standard 1]. Suggested audit and quality measures are identified in Table 7. Clinical quality measures.

Table 6. NSQHS Standard 1

<table>
<thead>
<tr>
<th>NSQHS Standard 1: Clinical governance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical performance and effectiveness</td>
</tr>
<tr>
<td>Criterion 1.27:</td>
</tr>
<tr>
<td>Actions required:</td>
</tr>
<tr>
<td>Evidence based care</td>
</tr>
<tr>
<td>a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice</td>
</tr>
<tr>
<td>b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care</td>
</tr>
</tbody>
</table>

The following clinical quality measures are suggested:

Table 7. Clinical quality measures

<table>
<thead>
<tr>
<th>No</th>
<th>Audit criteria</th>
<th>Guideline section</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Proportion of women that are given information about normal fetal movements early in pregnancy</td>
<td>Assessing fetal movements</td>
</tr>
<tr>
<td>2.</td>
<td>Proportion of women that are asked at each antenatal appointment to describe their baby’s fetal movements</td>
<td>Assessing fetal movements</td>
</tr>
<tr>
<td>3.</td>
<td>Proportion of women presenting with changed or decreased fetal movements who have a clinical assessment within two hours of presentation to their healthcare provider</td>
<td>Fetal movements</td>
</tr>
<tr>
<td>4.</td>
<td>Proportion of women presenting with changed or decreased fetal movements who have a CTG within two hours of presentation to their healthcare provider</td>
<td>Fetal movements</td>
</tr>
<tr>
<td>5.</td>
<td>Proportion of women presenting with changed or decreased fetal movements who have an obstetric USS performed, when required</td>
<td>Fetal movements</td>
</tr>
</tbody>
</table>

4.5 Areas for future research
During development the following areas were identified as having limited or poor quality evidence to inform clinical decision making. Further research in these areas may be useful.

- Appropriate screening tools to identify pregnancies at risk when the woman presents with changed fetal movements
- Appropriate interventions for women presenting with changed fetal movements
- Best practice management of women with recurrent changed fetal movements in the presence of normal assessment
- How frequently women with reduced fetal movements have abnormal Kleihauer-Betke or flow cytometry test results
### 4.6 Safety and quality

In conjunction with the Queensland Clinical Guideline *Standard care*\(^2\), implementation of this guideline provides evidence of compliance with the National Safety and Quality Health Service Standards.\(^1\)

#### Table 8. NSQHS

<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>☑ Evidence of compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSQHS Standard 1: Clinical governance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient safety and quality systems</td>
<td>Diversity and high risk groups</td>
<td>☐ Assessment and care appropriate to the cohort of patients is identified in the guideline</td>
</tr>
<tr>
<td>Safety and quality systems</td>
<td>1.15 The health service organisation: a. Identifies the diversity of the consumers using its services</td>
<td>☐ High risk groups are identified in the guideline</td>
</tr>
<tr>
<td></td>
<td>b. Identifies groups of patients using its services who are at higher risk of harm</td>
<td>☐ The guideline is based on the best available evidence</td>
</tr>
<tr>
<td></td>
<td>c. Incorporates information on the diversity of its consumers and higher-risk groups into the planning and delivery of care</td>
<td></td>
</tr>
<tr>
<td>Evidence based care</td>
<td>Evidence based care 1.27 The health service organisation has processes that: a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice</td>
<td>☐ Queensland Clinical Guidelines is funded by Queensland Health to develop clinical guidelines relevant to the service line to guide safe patient care across Queensland</td>
</tr>
<tr>
<td></td>
<td>b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care</td>
<td>☐ The guideline provides evidence-based and best practice recommendations for care</td>
</tr>
<tr>
<td></td>
<td>☐ The guideline is endorsed for use in Queensland Health facilities.</td>
<td>☐ The guideline is endorsed for use in Queensland Health facilities.</td>
</tr>
<tr>
<td></td>
<td>☐ A desktop icon is available on every Queensland Health computer desktop to provide quick and easy access to the guideline</td>
<td></td>
</tr>
<tr>
<td>Clinical performance and effectiveness</td>
<td>Performance management 1.22 The health service organisation has valid and reliable performance review processes that: a. Require members of the workforce to regularly take part in a review of their performance</td>
<td>☐ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet <a href="http://www.health.qld.gov.au/qcg">http://www.health.qld.gov.au/qcg</a></td>
</tr>
<tr>
<td>The workforce has the right qualifications, skills and supervision to provide safe, high-quality health care to patients.</td>
<td>b. Identify needs for training and development in safety and quality</td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. Incorporate information on training requirements into the organisation's training system</td>
<td></td>
</tr>
</tbody>
</table>
## NSQHS Criteria

### NSQHS Standard 1: Clinical governance

#### Patient safety and quality systems
Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.

<table>
<thead>
<tr>
<th>Policies and procedures</th>
<th>Evidence of compliance</th>
</tr>
</thead>
</table>
| 1.7 The health service organisation uses a risk management approach to:  
   a. Set out, review, and maintain the currency and effectiveness of, policies, procedures and protocols  
   b. Monitor and take action to improve adherence to policies, procedures and protocols  
   c. Review compliance with legislation, regulation and jurisdictional requirements |  
   QCG has established processes to review and maintain all guidelines and associated resources  
   Change requests are managed to ensure currency of published guidelines  
   Implementation tools and checklist are provided to assist with adherence to guidelines  
   Suggested audit criteria are provided in guideline supplement  
   The guidelines comply with legislation, regulation and jurisdictional requirements |

#### Health literacy
Health service organisations communicate with consumers in a way that supports effective partnerships.

<table>
<thead>
<tr>
<th>Communication that supports effective partnerships</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.8 The health service organisation uses communication mechanisms that are tailored to the diversity of the consumers who use its services and, where relevant, the diversity of the local community</td>
</tr>
<tr>
<td>2.9 Where information for patients, carers, families and consumers about health and health services is developed internally, the organisation involves consumers in its development and review</td>
</tr>
</tbody>
</table>
| 2.10 The health service organisation supports clinicians to communicate with patients, carers, families and consumers about health and health care so that:  
   a. Information is provided in a way that meets the needs of patients, carers, families and consumers  
   b. Information provided is easy to understand and use  
   c. The clinical needs of patients are addressed while they are in the health service organisation  
   d. Information needs for ongoing care are provided on discharge |  
| Consumer consultation was sought and obtained during the development of the guideline. Refer to the acknowledgement section of the guideline for details  
| Consumer information is developed to align with the guideline and included consumer involvement during development and review  
| The consumer information was developed using plain English and with attention to literacy and ease of reading needs of the consumer |

#### Partnering with consumers in organisational design and governance
 Consumers are partners in the design and governance of the organisation.

<table>
<thead>
<tr>
<th>Partnerships in healthcare governance planning, design, measurement and evaluation</th>
</tr>
</thead>
</table>
| 2.11 The health service organisation:  
   a. Involves consumers in partnerships in the governance of, and to design, measure and evaluate, health care  
   b. Has processes so that the consumers involved in these partnerships reflect the diversity of consumers who use the service or, where relevant, the diversity of the local community |  
| 2.14 The health service organisation works in partnership with consumers to incorporate their views and experiences into training and education for the workforce |  
| Consumers are members of guideline working parties  
| The guideline is based on the best available evidence  
| The guidelines and consumer information are endorsed by the QCG and Queensland Statewide Maternity and Neonatal Clinical Network Steering Committees which includes consumer membership |
### NSQHS Criteria

<table>
<thead>
<tr>
<th>NSQHS Standard 2: Partnering with Consumers</th>
<th>Actions required</th>
<th>☑️ Evidence of compliance</th>
</tr>
</thead>
</table>
| Partnering with consumers in their own care | Healthcare rights and informed consent  
2.4 The health service organisation ensures that its informed consent processes comply with legislation and best practice  
2.5 The health service organisation has processes to identify:  
a. The capacity of a patient to make decisions about their own care  
b. A substitute decision-maker if a patient does not have the capacity to make decisions for themselves | ☑️ This guideline and consumer information provides information for consumers to make informed decisions  
☑️ This guideline promotes informed consent |
| | Shared decisions and planning care  
2.6 The health service organisation has processes for clinicians to partner with patients and/or their substitute decision-maker to plan, communicate, set goals, and make decisions about their current and future care  
2.7 The health service organisation supports the workforce to form partnerships with patients and carers so that patients can be actively involved in their own care | ☑️ Consumer information is available for this guideline  
☑️ Consumers are members of guideline working parties |

| NSQHS Standard 3: Infection prevention and control systems | Integrating clinical governance  
3.1 The workforce uses the safety and quality systems from the Clinical Governance Standard when:  
a. Implementing policies and procedures for healthcare-associated infections and antimicrobial stewardship  
b. Managing risks associated with healthcare-associated infections and antimicrobial stewardship | ☑️ The guideline provides evidence-based and best practice recommendations for care  
☑️ Recommendations for use of antimicrobials are evidence based |

| Infection prevention and control systems | Standard and transmission-based precautions  
3.6 Clinicians assess infection risks and use transmission-based precautions based on the risk of transmission of infectious agents, and consider:  
a. Patients’ risks, which are evaluated at referral, on admission or on presentation for care, and re-evaluated when clinically required during care | ☑️ The guideline provides evidence-based and best practice recommendations for care  
☑️ Assessment and care appropriate to the cohort of patients is identified in the guideline  
☑️ High risk groups are identified in the guideline if applicable |

| Antimicrobial stewardship | Antimicrobial stewardship  
3.15 The health service organisation has an antimicrobial stewardship program that:  
a. Includes an antimicrobial stewardship policy  
b. Provides access to, and promotes the use of, current evidence-based Australian therapeutic guidelines and resources on antimicrobial prescribing | ☑️ The guideline provides evidence-based and best practice recommendations for care  
☑️ Recommendations for use of antimicrobials are evidence based  
☑️ If applicable, Australian therapeutic guidelines and resources were used to develop guideline recommendations |
<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSQHS Standard 4: Medication safety</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Clinical governance and quality improvement to support medication management | Integrating clinical governance  
4.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:  
a. Implementing policies and procedures for medication management  
b. Managing risks associated with medication management  
c. Identifying training requirements for medication management | ☑ The guideline provides current evidence based recommendations about medication |

| **NSQHS Standard 5: Comprehensive care** | | |
| Clinical governance and quality improvement to support comprehensive care | Integrating clinical governance  
5.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:  
a. Implementing policies and procedures for comprehensive care  
b. Managing risks associated with comprehensive care  
c. Identifying training requirements to deliver comprehensive care  
Partnering with consumers  
5.3 Clinicians use organisational processes from the Partnering with Consumers Standard when providing comprehensive care to:  
a. Actively involve patients in their own care  
b. Meet the patient's information needs  
c. Share decision-making | ☑ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet [http://www.health.qld.gov.au/qcg](http://www.health.qld.gov.au/qcg)  
☑ The guideline provides evidence-based and best practice recommendations for care  
☑ Consumer information is developed for the guideline |
### NSQHS Criteria

<table>
<thead>
<tr>
<th>NSQHS Standard 6: Communicating for safety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical governance and quality improvement to support effective communication</strong></td>
</tr>
<tr>
<td>Systems are in place for effective and coordinated communication that supports the delivery of continuous and safe care for patients.</td>
</tr>
<tr>
<td><strong>Integrating clinical governance</strong></td>
</tr>
<tr>
<td>6.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:</td>
</tr>
<tr>
<td>a. Implementing policies and procedures to support effective clinical communication</td>
</tr>
<tr>
<td>b. Managing risks associated with clinical communication</td>
</tr>
<tr>
<td>c. Identifying training requirements for effective and coordinated clinical communication</td>
</tr>
<tr>
<td><strong>Partnering with consumers</strong></td>
</tr>
<tr>
<td>6.3 Clinicians use organisational processes from the Partnering with Consumers Standard to effectively communicate with patients, carers and families during high-risk situations to:</td>
</tr>
<tr>
<td>a. Actively involve patients in their own care</td>
</tr>
<tr>
<td>b. Meet the patient’s information needs</td>
</tr>
<tr>
<td>c. Share decision-making</td>
</tr>
<tr>
<td><strong>Organisational processes to support effective communication</strong></td>
</tr>
<tr>
<td>6.4 The health service organisation has clinical communication processes to support effective communication when:</td>
</tr>
<tr>
<td>a. Identification and procedure matching should occur</td>
</tr>
<tr>
<td>b. All or part of a patient’s care is transferred within the organisation, between multidisciplinary teams, between clinicians or between organisations; and on discharge</td>
</tr>
<tr>
<td>c. Critical information about a patient’s care, including information on risks, emerges or changes</td>
</tr>
<tr>
<td><strong>Communication of critical information</strong></td>
</tr>
<tr>
<td>Systems to effectively communicate critical information and risks when they emerge or change are used to ensure safe patient care.</td>
</tr>
<tr>
<td><strong>Communicating critical information</strong></td>
</tr>
<tr>
<td>6.9 Clinicians and multidisciplinary teams use clinical communication processes to effectively communicate critical information, alerts and risks, in a timely way, when they emerge or change to:</td>
</tr>
<tr>
<td>a. Clinicians who can make decisions about care</td>
</tr>
<tr>
<td>b. Patients, carers and families, in accordance with the wishes of the patient</td>
</tr>
<tr>
<td>6.10 The health service organisation ensures that there are communication processes for patients, carers and families to directly communicate critical information and risks about care to clinicians</td>
</tr>
</tbody>
</table>

- Requirements for effective clinical communication by clinicians are identified
- The guideline provides evidence-based and best practice recommendations for communication between clinicians
- The guideline provides evidence-based and best practice recommendations for communication with patients, carers and families
- The guideline provides evidence-based and best practice recommendations for discharge planning and follow–up care
<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correct identification and procedure matching</td>
<td><strong>Correct identification and procedure matching</strong>&lt;br&gt;6.5 The health service organisation:&lt;br&gt;a. Defines approved identifiers for patients according to best-practice guidelines&lt;br&gt;b. Requires at least three approved identifiers on registration and admission; when care, medication, therapy and other services are provided; and when clinical handover, transfer or discharge documentation is generated</td>
<td>✓ Requirements for safe and for correct patient identification are identified</td>
</tr>
<tr>
<td>Communicating at clinical handover</td>
<td><strong>Clinical handover</strong>&lt;br&gt;6.7 The health service organisation, in collaboration with clinicians, defines the:&lt;br&gt;a. Minimum information content to be communicated at clinical handover, based on best-practice guidelines&lt;br&gt;b. Risks relevant to the service context and the particular needs of patients, carers and families&lt;br&gt;c. Clinicians who are involved in the clinical handover&lt;br&gt;6.8 Clinicians use structured clinical handover processes that include:&lt;br&gt;a. Preparing and scheduling clinical handover&lt;br&gt;b. Having the relevant information at clinical handover&lt;br&gt;c. Organising relevant clinicians and others to participate in clinical handover&lt;br&gt;d. Being aware of the patient’s goals and preferences&lt;br&gt;e. Supporting patients, carers and families to be involved in clinical handover, in accordance with the wishes of the patient&lt;br&gt;f. Ensuring that clinical handover results in the transfer of responsibility and accountability for care</td>
<td>✓ The guideline acknowledges the need for local protocols to support transfer of information, professional responsibility and accountability for some or all aspects of care</td>
</tr>
<tr>
<td>NSQHS Criteria</td>
<td>Actions required</td>
<td>Evidence of compliance</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>NSQHS Standard 7: Blood management</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical governance and quality improvement to support blood management</strong></td>
<td>Integrating clinical governance 7.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for blood management b. Managing risks associated with blood management c. Identifying training requirements for blood management</td>
<td>✓ The guideline provides evidence-based and best practice recommendations for use of blood products</td>
</tr>
<tr>
<td></td>
<td>Optimising and conserving patients’ own blood 7.4 Clinicians use the blood and blood products processes to manage the need for, and minimise the inappropriate use of, blood and blood products by: a. Optimising patients’ own red cell mass, haemoglobin and iron stores b. Identifying and managing patients with, or at risk of, bleeding c. Determining the clinical need for blood and blood products, and related risks</td>
<td>✓ The guideline provides evidence-based and best practice recommendations for use of blood products  ✓ The guideline is consistent with recommendations of national guidelines</td>
</tr>
<tr>
<td><strong>Prescribing and clinical use of blood and blood products</strong></td>
<td>Prescribing and administering blood and blood products 7.6 The health service organisation supports clinicians to prescribe and administer blood and blood products appropriately, in accordance with national guidelines and national criteria</td>
<td></td>
</tr>
<tr>
<td>NSQHS Criteria</td>
<td>Actions required</td>
<td>☑️ Evidence of compliance</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| NSQHS Standard 8: Recognising and responding to acute deterioration | **Integrating clinical governance**  
8.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:  
a. Implementing policies and procedures for recognising and responding to acute deterioration  
b. Managing risks associated with recognising and responding to acute deterioration  
c. Identifying training requirements for recognising and responding to acute deterioration  
**Partnering with consumers**  
8.3 Clinicians use organisational processes from the Partnering with Consumers Standard when recognising and responding to acute deterioration to:  
a. Actively involve patients in their own care  
b. Meet the patient’s information needs  
c. Share decision-making  
**Recognising acute deterioration**  
8.4 The health service organisation has processes for clinicians to detect acute physiological deterioration that require clinicians to:  
a. Document individualised vital sign monitoring plans  
b. Monitor patients as required by their individualised monitoring plan  
c. Graphically document and track changes in agreed observations to detect acute deterioration over time, as appropriate for the patient | ☑️ The guideline is consistent with National Consensus statements recommendations  
☑️ The guideline recommends use of tools consistent with the principles of recognising and responding to clinical deterioration  
☑️ Consumer information is developed for the guideline |

Clinical governance and quality improvement to support recognition and response systems  
Organisation-wide systems are used to support and promote detection and recognition of acute deterioration, and the response to patients whose condition acutely deteriorates.
References


Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Leads
Dr Scott Petersen, Staff Specialist, Maternal Fetal Medicine, Mater Mother’s Hospital
Ms Simone Naughton, Regional Maternity Services Coordinator, Cairns Hospital

QCG Program Officer
Ms Emily Holmes, Clinical Midwife Consultant

Working party membership
Dr Sue (Siew) Goh, Rural Generalist/Obstetrician, Dalby Base Hospital
Ms Sophie Schipplock, Clinical Midwife Consultant, Maternal Fetal Medicine, Gold Coast University Hospital
Ms Melanie McKenzie, Consumer Representative, Harrison’s Little Wings
Ms Eileen Cooke, Consumer Representative, Preterm Infants Parents Association
Ms Rukhsana Aziz, Clinical Midwifery Consultant, Torres and Cape Hospital and Health Service
Dr Terry Sheahan, Obstetrician, Northwest Private Hospital
Dr Lindsay Cochrane, Obstetrician, Caboolture Hospital
Ms Sue Bloomfield, Sonographer, Townsville Hospital
Ms Anna De Bosch, Maternity Health Worker, Cairns Hospital
Ms Sally Brunton, Acting Midwifery Unit Manager, Mater Mother’s Hospital
Dr Renuka Sekar, Clinical Lead Maternal and Fetal Medicine, Royal Brisbane and Women’s Hospital

Queensland Clinical Guidelines Team
Professor Rebecca Kimble, Director
Ms Jacinta Lee, Manager
Ms Stephanie Sutherns, Clinical Nurse Consultant
Ms Cara Cox, Clinical Nurse Consultant
Ms Emily Holmes, Clinical Nurse Consultant
Ms Janene Rattray, Clinical Nurse Consultant
Ms Jacqueline Plazina, Clinical Nurse Consultant
Steering Committee